Conditions: Hepatitis D, Chronic
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 12
Healthy volunteers: no

Brief summary:
This single-center, randomized, open-label, pilot study is designed to evaluate the efficacy and safety of 48 weeks of treatment with peginterferon alfa-2a alone versus in combination with ribavirin in participants with CHD.

Detailed description:

Arms:
arm 1: Participants will receive peginterferon alfa-2a alone, administered over 48 weeks. arm 2: Participants will receive combination therapy with peginterferon alfa-2a plus ribavirin, administered over 48 weeks.

Interventions: intervention 1: Peginterferon alfa-2a intervention 2: Ribavirin
Intervention descriptions: intervention 1: Peginterferon alfa-2a will be administered as 180 micrograms (mcg) once weekly via subcutaneous (SC) injection. intervention 2: Ribavirin will be administered as 1000 to 1200 milligrams (mg) per day in divided oral doses.

Protocol document: